The delay dovetails with moves by Republican lawmakers in at least 7 states to ban or limit mRNA vaccines. Some, according to KFF Health News, are also pressing regulators to revoke federal approval ...

Novavax NVAX shares soared 11.4% in the last trading session to close at $6.24. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the ...

The delay follows leadership changes within the FDA. Dr. Scott Steele has been appointed acting director of the agency’s ...

We recently published a list of 10 Unstoppable Stocks That Could Double Your Money. In this article, we are going to take a ...

Kennedy, a well-known vaccine skeptic, last week announced plans to reshape federal public health agencies, including cutting ...

As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...

The FDA was supposed to make a final decision about approval of Novavax's COVID-19 vaccine this week, but that deadline has ...

The FDA has delayed granting full approval of Novavax's COVID-19 vaccine despite it being on track to be cleared until ...

Amid a period of great upheaval at the agency, the FDA has missed its deadline to decide on approval for Novavax’s COVID-19 ...

Novavax started the week hoping the FDA would issue a full approval of its Covid vaccine. But the decision never came.

Novavax's COVID-19 vaccine received FDA Emergency Use Authorization, but full approval faces delays as regulators request more data beyond the April 1 deadline.

It reported revenues of 38.41 million yuan in the first half of 2024 and a net loss of 903 million yuan, hit by falling ...